Boston Scientific Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Boston Scientific Corporation on February 12, 2025, covering an event dated February 9, 2025. The filing addresses corporate governance changes regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to Item 5.02 regarding officer departures and does not contain financial performance data.
Material Changes
The material change reported is the departure of Charles J. Dockendorff from the Board of Directors. Mr. Dockendorff, who has served since April 2015 and currently sits on the Audit and Risk Committees, will not stand for re-election at the 2025 Annual Meeting of Stockholders. He will continue to serve in his current roles until that meeting concludes.
Guidance, Outlook, and Risks
Management states that Mr. Dockendorff's decision is not the result of any disagreement with the Company. The Board and Nominating and Governance Committee will evaluate whether to add new directors following his departure. No financial guidance, outlook, or specific risk factors were disclosed in this filing.
Key Facts for Investors
- Charles J. Dockendorff will not seek re-election as a director at the 2025 Annual Meeting.
- Mr. Dockendorff remains on the Board and its committees until the 2025 Annual Meeting.
- The departure is voluntary and not due to any disagreement with the Company.
- The Board will assess the need to appoint a replacement director after the Annual Meeting.